Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307044474> ?p ?o ?g. }
- W4307044474 endingPage "100373" @default.
- W4307044474 startingPage "100373" @default.
- W4307044474 abstract "The field of antisense oligonucleotide (ASO)-based therapies have been making strides in precision medicine due to their potent therapeutic application. Early successes in treating some genetic diseases are now attributed to an emerging class of antisense drugs. After two decades, the US Food and Drug Administration (FDA) has approved a considerable number of ASO drugs, primarily to treat rare diseases with optimal therapeutic outcomes. However, safety is one of the biggest challenges to the therapeutic utility of ASO drugs. Due to patients' and health care practitioners' urgent demands for medicines for untreatable conditions, many ASO drugs have been approved. However, a complete understanding of the mechanisms of adverse drug reactions (ADRs) and toxicities of ASOs still need to be resolved. The range of ADRs is unique to a specific drug, while few ADRs are common to a section of drugs as a whole. Nephrotoxicity is an important concern that needs to be addressed considering the clinical translation of any drug candidates ranging from small molecules to ASO-based drugs. This article encompasses what is known about the nephrotoxicity of ASO drugs, the potential mechanisms of action(s), and recommendations for future investigations on the safety of ASO drugs." @default.
- W4307044474 created "2022-10-23" @default.
- W4307044474 creator A5003882684 @default.
- W4307044474 creator A5017241123 @default.
- W4307044474 creator A5019917020 @default.
- W4307044474 creator A5028348416 @default.
- W4307044474 creator A5030329823 @default.
- W4307044474 creator A5049068235 @default.
- W4307044474 creator A5060593392 @default.
- W4307044474 creator A5062625465 @default.
- W4307044474 creator A5064164166 @default.
- W4307044474 creator A5069256055 @default.
- W4307044474 creator A5083121536 @default.
- W4307044474 date "2022-12-01" @default.
- W4307044474 modified "2023-10-10" @default.
- W4307044474 title "Nephrotoxicity of marketed antisense oligonucleotide drugs" @default.
- W4307044474 cites W1550638692 @default.
- W4307044474 cites W1905908978 @default.
- W4307044474 cites W2163073102 @default.
- W4307044474 cites W2304098217 @default.
- W4307044474 cites W2473879127 @default.
- W4307044474 cites W2567195420 @default.
- W4307044474 cites W2583673989 @default.
- W4307044474 cites W2595650684 @default.
- W4307044474 cites W2765483614 @default.
- W4307044474 cites W2769583052 @default.
- W4307044474 cites W2774176529 @default.
- W4307044474 cites W2789114047 @default.
- W4307044474 cites W2799858598 @default.
- W4307044474 cites W2809989268 @default.
- W4307044474 cites W2886103485 @default.
- W4307044474 cites W2889214184 @default.
- W4307044474 cites W2890315635 @default.
- W4307044474 cites W2900955439 @default.
- W4307044474 cites W2905331745 @default.
- W4307044474 cites W2919508985 @default.
- W4307044474 cites W2920438880 @default.
- W4307044474 cites W2922600469 @default.
- W4307044474 cites W2936801925 @default.
- W4307044474 cites W2942765605 @default.
- W4307044474 cites W2943158117 @default.
- W4307044474 cites W2943221610 @default.
- W4307044474 cites W2943738258 @default.
- W4307044474 cites W2946162392 @default.
- W4307044474 cites W2968712798 @default.
- W4307044474 cites W2971476125 @default.
- W4307044474 cites W2971637923 @default.
- W4307044474 cites W2981233941 @default.
- W4307044474 cites W2995227437 @default.
- W4307044474 cites W2997805527 @default.
- W4307044474 cites W3006387795 @default.
- W4307044474 cites W3009001990 @default.
- W4307044474 cites W3015010867 @default.
- W4307044474 cites W3018892538 @default.
- W4307044474 cites W3030480398 @default.
- W4307044474 cites W3033007748 @default.
- W4307044474 cites W3037517625 @default.
- W4307044474 cites W3047556542 @default.
- W4307044474 cites W3048948207 @default.
- W4307044474 cites W3086603080 @default.
- W4307044474 cites W3112046530 @default.
- W4307044474 cites W3121560287 @default.
- W4307044474 cites W3123502642 @default.
- W4307044474 cites W3135238293 @default.
- W4307044474 cites W3137153690 @default.
- W4307044474 cites W3155362558 @default.
- W4307044474 cites W3159189176 @default.
- W4307044474 cites W3166174049 @default.
- W4307044474 cites W3167186946 @default.
- W4307044474 cites W3201593259 @default.
- W4307044474 cites W3212228890 @default.
- W4307044474 cites W3212518559 @default.
- W4307044474 cites W4200087363 @default.
- W4307044474 cites W4200179740 @default.
- W4307044474 cites W4205923643 @default.
- W4307044474 cites W4206922281 @default.
- W4307044474 cites W4214596965 @default.
- W4307044474 cites W4214717665 @default.
- W4307044474 cites W4252392290 @default.
- W4307044474 cites W4281385867 @default.
- W4307044474 cites W4286915844 @default.
- W4307044474 doi "https://doi.org/10.1016/j.cotox.2022.100373" @default.
- W4307044474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37193356" @default.
- W4307044474 hasPublicationYear "2022" @default.
- W4307044474 type Work @default.
- W4307044474 citedByCount "1" @default.
- W4307044474 crossrefType "journal-article" @default.
- W4307044474 hasAuthorship W4307044474A5003882684 @default.
- W4307044474 hasAuthorship W4307044474A5017241123 @default.
- W4307044474 hasAuthorship W4307044474A5019917020 @default.
- W4307044474 hasAuthorship W4307044474A5028348416 @default.
- W4307044474 hasAuthorship W4307044474A5030329823 @default.
- W4307044474 hasAuthorship W4307044474A5049068235 @default.
- W4307044474 hasAuthorship W4307044474A5060593392 @default.
- W4307044474 hasAuthorship W4307044474A5062625465 @default.
- W4307044474 hasAuthorship W4307044474A5064164166 @default.
- W4307044474 hasAuthorship W4307044474A5069256055 @default.
- W4307044474 hasAuthorship W4307044474A5083121536 @default.